Artwork

Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma

12:51
 
Share
 

Manage episode 296721464 series 2947447
Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.”

Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.

  continue reading

58 episodes

Artwork
iconShare
 
Manage episode 296721464 series 2947447
Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Rick Greene, MD, and Melissa Hogg, MD, discuss the relationship of serum CA19-9 to other markers of response, and the related thresholds correlating to outcomes, following neoadjuvant therapy for pancreatic adenocarcinoma. Dr. Hogg is author of the article, “Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.”

Dr. Hogg is the Director of HPB Surgery and Director of Robotic Training for Grainger Lab at the Northshore University Healthsystem, Chicago, IL.

  continue reading

58 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide